IL-12-secreting CAR-T cells reprogram the tumor microenvironment and improve efficacy against heterogeneous models of glioblastoma - PubMed
4 hours ago
- #Glioblastoma
- #CAR-T cells
- #Immunotherapy
- IL-12-secreting CAR-T cells target EGFRvIII in glioblastoma (GBM) models.
- These CAR-T cells achieved 50% long-term survival in mice without lymphodepletion.
- Therapeutic efficacy depends on endogenous CD8+ T cells, not natural killer cells.
- IL-12 enhances CAR-T cell persistence and reprograms tumor-associated microglia.
- The strategy addresses tumor heterogeneity by engaging adaptive immunity against antigen-negative clones.
- Potential clinical benefits include avoiding toxic lymphodepletion and improving GBM outcomes.